Literature DB >> 9189655

Structural identifiability of PBPK models: practical consequences for modeling strategies and study designs.

W Slob1, P H Janssen, J M van den Hof.   

Abstract

Physiologically based pharmacokinetic (PBPK) models usually contain unknown parameters that need to be estimated by calibration to concentration-time profiles from in vivo experiments. However, even with error-free data, the number of parameters that can be estimated in this way is limited, depending on the particular situation. This paper introduces the concept of structural identifiability of a model, a requirement to make the estimation of parameters by calibration a meaningful undertaking. We briefly discuss the techniques-available from systems analysis-for examining the identifiability of models. Two conditions of uniqueness are involved, one relating to the model's equations and its parameters, the other to the number of available observations in time. The assessment of the first uniqueness condition involves rather tedious matrix algebra, requiring the appropriate mathematical expertise. We therefore give some general results for a particular class of PBPK models, indicating in what situations the first uniqueness condition either holds or does not. The assessment of the second uniqueness condition does not require specialized skills, and the minimum number of observations in time necessary can be easily determined for any particular situation. The practical implications for both modeling strategies and experimental protocols are discussed.

Mesh:

Year:  1997        PMID: 9189655     DOI: 10.3109/10408449709089895

Source DB:  PubMed          Journal:  Crit Rev Toxicol        ISSN: 1040-8444            Impact factor:   5.635


  9 in total

Review 1.  Whole body pharmacokinetic models.

Authors:  Ivan Nestorov
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 2.  Combining the 'bottom up' and 'top down' approaches in pharmacokinetic modelling: fitting PBPK models to observed clinical data.

Authors:  Nikolaos Tsamandouras; Amin Rostami-Hodjegan; Leon Aarons
Journal:  Br J Clin Pharmacol       Date:  2015-01       Impact factor: 4.335

Review 3.  In vitro to in vivo extrapolation for high throughput prioritization and decision making.

Authors:  Shannon M Bell; Xiaoqing Chang; John F Wambaugh; David G Allen; Mike Bartels; Kim L R Brouwer; Warren M Casey; Neepa Choksi; Stephen S Ferguson; Grazyna Fraczkiewicz; Annie M Jarabek; Alice Ke; Annie Lumen; Scott G Lynn; Alicia Paini; Paul S Price; Caroline Ring; Ted W Simon; Nisha S Sipes; Catherine S Sprankle; Judy Strickland; John Troutman; Barbara A Wetmore; Nicole C Kleinstreuer
Journal:  Toxicol In Vitro       Date:  2017-12-05       Impact factor: 3.500

4.  Identifiability of PBPK models with applications to dimethylarsinic acid exposure.

Authors:  Ramon I Garcia; Joseph G Ibrahim; John F Wambaugh; Elaina M Kenyon; R Woodrow Setzer
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-07-21       Impact factor: 2.745

Review 5.  Physiologically Based Pharmacokinetic Model Qualification and Reporting Procedures for Regulatory Submissions: A Consortium Perspective.

Authors:  Mohamad Shebley; Punam Sandhu; Arian Emami Riedmaier; Masoud Jamei; Rangaraj Narayanan; Aarti Patel; Sheila Annie Peters; Venkatesh Pilla Reddy; Ming Zheng; Loeckie de Zwart; Maud Beneton; Francois Bouzom; Jun Chen; Yuan Chen; Yumi Cleary; Christiane Collins; Gemma L Dickinson; Nassim Djebli; Heidi J Einolf; Iain Gardner; Felix Huth; Faraz Kazmi; Feras Khalil; Jing Lin; Aleksandrs Odinecs; Chirag Patel; Haojing Rong; Edgar Schuck; Pradeep Sharma; Shu-Pei Wu; Yang Xu; Shinji Yamazaki; Kenta Yoshida; Malcolm Rowland
Journal:  Clin Pharmacol Ther       Date:  2018-02-02       Impact factor: 6.875

6.  Lost in modelling and simulation?

Authors:  Kiyohiko Sugano
Journal:  ADMET DMPK       Date:  2021-03-22

7.  Analysis of cellular kinetic models suggest that physiologically based model parameters may be inherently, practically unidentifiable.

Authors:  Liam V Brown; Mark C Coles; Mark McConnell; Alexander V Ratushny; Eamonn A Gaffney
Journal:  J Pharmacokinet Pharmacodyn       Date:  2022-08-06       Impact factor: 2.410

8.  Pregnancy-specific physiologically-based toxicokinetic models for bisphenol A and bisphenol S.

Authors:  Jeremy Gingrich; David Filipovic; Rory Conolly; Sudin Bhattacharya; Almudena Veiga-Lopez
Journal:  Environ Int       Date:  2020-12-22       Impact factor: 9.621

9.  Applying a Global Sensitivity Analysis Workflow to Improve the Computational Efficiencies in Physiologically-Based Pharmacokinetic Modeling.

Authors:  Nan-Hung Hsieh; Brad Reisfeld; Frederic Y Bois; Weihsueh A Chiu
Journal:  Front Pharmacol       Date:  2018-06-08       Impact factor: 5.810

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.